I9X-MC-MTAE: Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512295-36-00

Acronym

I9X-MC-MTAE

Enrollment

Registered

2024-11-26

Start date

2021-12-06

Completion date

2025-03-31

Last updated

2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)

Interventions

DRUGFlortaucipir

DRUGPlacebo to match LY3372689

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026